Cazenove Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Cazenove Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q2	$45.6K	Buy	+570	New	+$42K	0.04%	131

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cazenove Capital Management's VRTX Position: Q2 2013 in Review

Cazenove Capital Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2013: 570 shares worth $45.6K. The stake represents 0.04% of the portfolio and ranks #131 among its holdings.

376 funds tracked by Wall St. Rank hold VRTX as of Q2 2013.

Cazenove Capital Management held 570 shares of Vertex Pharmaceuticals worth $45.6K as of Q2 2013.
Vertex Pharmaceuticals was a new Cazenove Capital Management position in Q2 2013.
Vertex Pharmaceuticals made up 0.04% of Cazenove Capital Management's portfolio in Q2 2013, its #131 holding.
376 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2013.

Based on Cazenove Capital Management's 13F filing for Q2 2013, filed 14 Aug 2013.